Thus, if a role can be ascribed to CCDC6 in the activation of the EGFR signaling, the detection of CCDC6 impairment upon TK fusion could represent an indication for targeting EGFR in cancer therapy (Cerrato A, Di Domenico I, Morra F, Celetti A, manuscript in preparation). Here, TKT is linked to cancer.